Bispecific antibodies to pd-1 and ctla4: Doubling down on t cells to decouple efficacy from toxicity

Elizabeth M. Burton; Hussein A. Tawbi

doi:10.1158/2159-8290.CD-21-0257

Bispecific antibodies to pd-1 and ctla4: Doubling down on t cells to decouple efficacy from toxicity

Elizabeth M. Burton, Hussein A. Tawbi

Melanoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity.

Original language	English (US)
Pages (from-to)	1008-1010
Number of pages	3
Journal	Cancer discovery
Volume	11
Issue number	5
DOIs	https://doi.org/10.1158/2159-8290.CD-21-0257
State	Published - May 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-21-0257

Cite this

@article{2936a57736df463f8b44d6e4680e32be,

title = "Bispecific antibodies to pd-1 and ctla4: Doubling down on t cells to decouple efficacy from toxicity",

abstract = "Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity.",

author = "Burton, {Elizabeth M.} and Tawbi, {Hussein A.}",

note = "Funding Information: H.A. Tawbi reports grants and personal fees from BMS, Merck, Novartis, and Genentech, personal fees from Eisai and Iovance, and grants from Celgene and GSK outside the submitted work. No disclosures were reported by the other author. Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = may,

doi = "10.1158/2159-8290.CD-21-0257",

language = "English (US)",

volume = "11",

pages = "1008--1010",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Bispecific antibodies to pd-1 and ctla4

T2 - Doubling down on t cells to decouple efficacy from toxicity

AU - Burton, Elizabeth M.

AU - Tawbi, Hussein A.

N1 - Funding Information: H.A. Tawbi reports grants and personal fees from BMS, Merck, Novartis, and Genentech, personal fees from Eisai and Iovance, and grants from Celgene and GSK outside the submitted work. No disclosures were reported by the other author. Publisher Copyright: © 2021 American Association for Cancer Research.

PY - 2021/5

Y1 - 2021/5

N2 - Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity.

AB - Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85105531045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105531045&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-21-0257

DO - 10.1158/2159-8290.CD-21-0257

M3 - Article

C2 - 33947716

AN - SCOPUS:85105531045

SN - 2159-8274

VL - 11

SP - 1008

EP - 1010

JO - Cancer discovery

JF - Cancer discovery

IS - 5

ER -

Bispecific antibodies to pd-1 and ctla4: Doubling down on t cells to decouple efficacy from toxicity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this